In light of the aforementioned results of subgroup analyses from randomized trials [113,114,115,116,117,118,119], upfront TKIs are currently accepted by international guidelines for selected patients with multiple asymptomatic BMs from EGFR-mutated and ALK-translocated NSCLC [51,52,53]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.